In last trading session, Lyell Immunopharma Inc (NASDAQ:LYEL) saw 0.72 million shares changing hands with its beta currently measuring -0.23. Company’s recent per share price level of $0.46 trading at -$0.01 or -0.04% at ring of the bell on the day assigns it a market valuation of $137.22M. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.69 million shares which gives us an average trading volume of 1.03 million if we extend that period to 3-months.
For Lyell Immunopharma Inc (LYEL), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 3.33. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
Upright in the red during last session for losing -0.04%, in the last five days LYEL remained trading in the red while hitting it’s week-highest on Monday, 03/31/25 when the stock touched $0.46 price level, adding 19.01% to its value on the day. Lyell Immunopharma Inc’s shares saw a change of -27.37% in year-to-date performance and have moved -14.12% in past 5-day. Lyell Immunopharma Inc (NASDAQ:LYEL) showed a performance of -36.01% in past 30-days. Number of shares sold short was 5.98 million shares which calculate 6.41 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 1 to the stock, which implies a rise of 54.0% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 1. It follows that stock’s current price would drop -117.39% in reaching the projected high whereas dropping to the targeted low would mean a loss of -117.39% for stock’s current value.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
This year revenue growth is estimated to fall -100.00% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -19.90% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 43.61% while estimates for its earnings growth in next 5 years are of 21.29%.
Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders
Insiders are in possession of 13.73% of company’s total shares while institution are holding 65.93 percent of that, with stock having share float percentage of 76.42%. Investors also watch the number of corporate investors in a company very closely, which is 65.93% institutions for Lyell Immunopharma Inc that are currently holding shares of the company. MWG MANAGEMENT LTD. is the top institutional holder at LYEL for having 20.16 million shares of worth $29.24 million. And as of 2024-06-30, it was holding 7.8945 of the company’s outstanding shares.
The second largest institutional holder is ORLAND PROPERTIES LTD, which was holding about 15.09 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.91 of outstanding shares, having a total worth of $21.89 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price Health Sciences Fund, Inc. are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 5.64 shares of worth $2.62 million or 1.91% of the total outstanding shares. The later fund manager was in possession of 4.94 shares on Dec 31, 2024 , making its stake of worth around $2.3 million in the company or a holder of 1.67% of company’s stock.
